Media Center
Publications
Phase 2 of Pro-Autophagic Drug ABTL0812 in Combination With First-Line Paclitaxel and Carboplatin in IIIb/IV Squamous NSCLC
IASLC, 2020 World Conference on Lung Cancer, Singapore, January 2021
Phase 2 of ABTL0812, a pro-autophagic drug, in combination with paclitaxel and carboplatin as first-line treatment in advanced/recurrent endometrial cancer
ESMO 2020 - Abstract 2727
C. Domènech , J. Alfon, I. Ray-Coquard, A. Oaknin
The anti-cancer drug ABTL0812 induces ER stress-mediated cytotoxic autophagy by increasing dihydroceramide levels in cancer cells.
Posted online: 13 May 2020
https://doi.org/10.1080/15548627.2020.1761651
Phase 1 of ABTL0812, a proautophagic drug, in combination with paclitaxel and carboplatin at first-line in advanced endometrial cancer and squamous cell lung carcinoma
Meeting: 2019 ASCO Annual Meeting - Abstract No: 3089 - Poster Board Number: Poster Session (Board 81) - Citation: J Clin Oncol 37, 2019 (suppl; abstr 3089)
Therapeutic potential of the new TRIB3-mediated cell autophagy anticancer drug ABTL0812 in endometrial cancer.
Published: Gynecol Oncol. 2019 Mar 7
S0090-8258(19)30150-7
ABTL0812, a novel phase-2 clinical stage pro-autophagic anti-cancer compound with potential clinical activity in cholangiocarcinoma
2019 Cholangiocarcinoma Foundation Annual Conference
Preclinical and clinical development of ABTL0812: a new antitumoral drug that induces autophagy-mediated cancer cell death by upregulating TRIB3 pseudokinase and impairing of Akt/mTORC1 axis.
1st Oncobell Symposium. Mechanisms of Cancer and New Therapeutic Strategies. Barcelona 2018.
Exploring pharmacokinetic/pharmacodynamic considerations in translational oncology; from preclinical development to Phase II operations
Outsourcing in Clinical Trials. Barcelona 2018.
Preclinical and clinical development of ABTL0812: a new antitumoral drug that induces autophagy-mediated cancer cell death by upregulating TRIB3 pseudokinase and impairing of Akt/mTORC1 axis.
16th International Congress ASEICA, 2018.
Development of TRIB3 as a novel preclinical and clinical pharmacodynamic biomarker for ABTL0812
J Clin Oncol 36, 2018 (suppl; abstr e14556).
The new antitumoral drug ABTL0812 induces autophagic cell death by a dual mechanism: inhibition of Akt/mTORC1 axis and impairing desaturase-1 activity.
Transautophagy, Copenhaguen 2017.
Determination of recommended phase II dose of ABTL0812, a novel regulator of Akt/mTOR axis, by pharmacokinetic-pharmacodynamic modelling
Published: 11 Oct. 2016
Ann Oncol (2016) 27 (suppl_6): 378P
The New Antitumor Drug ABTL0812 Inhibits the Akt/mTORC1 Axis by Upregulating Tribbles-3 Pseudokinase
Published: 15 May 2016 10.1158/1078-0432.CCR-15-1808
LATEST NEWS
Press Release
The Chinese pharmaceutical company SciClone joins the capital of AbilityPharma with an investment commitment of three million dollars + infoPress Release
The antitumoral drug ABTL0812 shows promising results against neuroblastoma + infoPress Release
AbilityPharma receives the approval from the FDA and the AEMPS to start the clinical trial of its molecule against pancreatic cancer in the US and Spain + infoPress Release
AbilityPharma receives a 1.6 million euro grant from the FDA and opens a crowdfunding campaign in Capital Cell + infoPress Release
ABILITYPHARMA PRESENTS THE RESULTS OF A NEW FIRST-LINE TREATMENT FOR ENDOMETRIAL CANCER + infoPress Release
AbilityPharma publishes full characterization of mechanism of action of ABTL0812, a Phase II clinical inducer of cytotoxic autophagy in cancer cells, in Autophagy journal + infoPress Release
AbilityPharma awarded €5 million from the Horizon Europe EIC Accelerator Pilot Program to conduct a Phase 2b clinical trial with ABTL0812 in patients with advanced pancreatic cancer + infoPress Release
AbilityPharma rises € 3.5 million in a financing round to complete the current oncologic phase 2 clinical trial and license ABTL0812 to an international pharmaceutical company + infoPress Release
Ability Pharmaceuticals Announces the Presentation of the First Results of ABTL0812 as First Line in Patients with Endometrial or Lung Cancer at 2019 ASCO Annual Meeting + info